Vetstoria vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary Online Appointment Booking Platform
Real-time online appointment booking platform for veterinary practices; Dublin Ireland; raised $8M+; integrates with ezyVet, Provet Cloud, Cornerstone, and Avimark to synchronize 24/7 online bookings with clinic PIMS; serves thousands of vet practices globally.
About
Vetstoria is a real-time online appointment booking platform built specifically for veterinary practices, enabling pet owners to book appointments online 24/7 through a clinic's website without phone calls, while giving veterinary teams full control over appointment types, availability, and booking rules. Founded in 2016 and headquartered in Dublin, Ireland, Vetstoria has raised approximately $8 million and grown to serve thousands of veterinary practices globally in Europe, the US, Australia, and Asia, integrating with leading practice management systems to synchronize appointments in real time.\n\nVetstoria's booking platform connects directly to a clinic's veterinary information management system — including ezyVet, Provet Cloud, Cornerstone, Avimark, and others — so bookings made online appear immediately in the practice schedule without staff intervention, and availability shown to clients accurately reflects real-time slot availability. Clinics control which appointment types are bookable online, can set deposit requirements for high-demand slots, and can restrict booking access to existing clients only. Analytics provide data on booking conversion rates, booking source (website, Google, social), and time-of-day patterns.\n\nVetstoria competes with PetDesk, Vetster, and general appointment booking platforms adapted from human healthcare in the veterinary booking space. Its deep PIMS integrations and purpose-built veterinary rules engine — which can handle species-specific booking logic, new patient workflows, and emergency appointment routing — differentiate it from generic online booking tools. The platform helps veterinary practices capture after-hours booking demand, reduce front-desk call volume, and improve the client experience for digitally-oriented pet owners.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.